AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
FDA Greenlights Aldosterone Synthase Inhibitor, Opening a New Front in Hypertension Treatment
The FDA has approved an aldosterone synthase inhibitor for hypertension, adding a new mechanism to the blood pressure treatment toolkit. The decision matters because it targets a hormonal pathway long seen as promising but hard to drug cleanly.
AI-Powered ECGs Could Turn a Routine Test Into a Long-Term Stroke Risk Predictor
A new approach uses 12-lead ECGs to estimate long-term stroke risk, potentially transforming a standard cardiac test into a broader screening tool. If validated, the method could help clinicians identify at-risk patients earlier, before symptoms or events occur.
How Bunkerhill Health’s CMS Win Signals a New Business Model for AI Cardiology
Bunkerhill Health has secured CMS payment for its AI-based cardiac analysis, a milestone that matters as much for reimbursement as for technology. The decision suggests AI tools are moving from pilot projects into the messy but crucial economics of routine care.
AI-powered ECG software wins recognition as hyperkalemia detection gains momentum
MedTech Breakthrough named an AI-powered hyperkalemia detection tool the best new ECG technology solution, signaling growing interest in using routine cardiac signals to detect metabolic risk. The recognition reflects a broader trend: AI is extending the value of existing diagnostics rather than replacing them.
Caranx Medical’s AI TAVI-TAVR software gains FDA approval, signaling deeper AI entry into structural heart care
Caranx Medical has won FDA approval for its AI software supporting TAVI-TAVR procedures. The clearance points to growing confidence in procedural AI, where tools can assist planning and execution in high-stakes cardiovascular care.
Abbott’s AI Imaging Device Win Shows Cardiology Is Becoming an AI Product Category
Abbott’s latest FDA and CE mark wins reinforce how quickly AI-enabled imaging tools are moving into mainstream cardiology. The bigger story is that regulatory approval is turning these systems from research novelties into commercial product lines with global reach.
Next-Gen Coronary Imaging Platform Wins FDA and CE Clearance, Expanding AI’s Role in Cardiology
A new AI-powered coronary imaging platform has secured both FDA clearance and a CE Mark, giving it access to major U.S. and European markets. The approval adds to the steady stream of AI imaging clearances, but also raises the bar for demonstrating clinical utility beyond technical performance.
Abbott’s Ultreon 3.0 Clearance Shows Cardiology AI Is Entering Its Productization Phase
Abbott has secured FDA clearance and CE Mark for Ultreon 3.0, its next-generation AI-powered coronary imaging platform. The milestone signals that cardiovascular AI is moving from promising software capability to regulated, commercially scaled infrastructure inside cath labs.
Coronary plaque AI tools face the next hurdle: reimbursement
A Cardiovascular Business article explains how to implement AI-powered coronary plaque analysis software while still getting paid for it. The piece underscores a key reality in healthcare AI: clinical usefulness is necessary, but reimbursement determines whether adoption can scale.
Abbott Wins FDA and EU Clearance for Ultreon 3.0, Strengthening AI Imaging Momentum
Abbott has secured both FDA and EU clearance for Ultreon 3.0, its AI-powered coronary imaging platform. The dual approvals strengthen Abbott’s position in a fast-moving market where AI is becoming a core feature of diagnostic and interventional tools.
FDA clears Conavi Medical’s next-generation hybrid IVUS-OCT imaging system
Conavi Medical has won FDA approval for its next-generation hybrid IVUS-OCT system, a device that combines two imaging modalities in one platform. The clearance is important because it reflects steady regulatory support for more sophisticated intravascular imaging tools. It may also strengthen the case for multimodal diagnostics that give clinicians more complete information during procedures.
Chinese Medical Journal Review Explores Where AI Fits in Heart Failure Care
A new review examines how artificial intelligence could be used across the heart failure pathway, from earlier detection to treatment optimization. The topic matters because heart failure is a high-burden condition where better prediction and monitoring could have outsized impact.
FDA Clears Anumana’s Pulmonary Hypertension Algorithm
Anumana has won FDA approval for an algorithm designed to detect pulmonary hypertension, adding to the wave of algorithm-based cardiovascular tools entering the clinic. The clearance reinforces how AI is increasingly being regulated as a medical product rather than a research experiment.
FDA Clears a New Transseptal Puncture Device, Targeting a High-Stakes Cardiology Procedure
Protaryx Medical has secured FDA clearance for a transseptal puncture device used in a highly specialized cardiac procedure. The approval matters because devices that reduce procedural complexity can influence both safety and how quickly minimally invasive cardiology techniques spread.
FDA Clears Protaryx’s Transseptal Puncture Device, Adding Momentum in Structural Heart
Protaryx has won FDA clearance for a transseptal puncture device, a procedural tool that could matter in structural heart interventions. While not as headline-grabbing as AI, this approval reflects steady innovation in core cardiovascular tooling.
Heartflow and Cleerly Fight Over the Future of Cardiac AI Competition
Heartflow’s lawsuit against AI rival Cleerly highlights how competitive pressure in cardiovascular imaging is shifting from clinical validation to intellectual property. The dispute suggests the market is maturing enough that legal strategy now matters alongside algorithm performance.
FDA Clears Protaryx Medical’s Transseptal Device, Targeting Easier Left-Heart Access
The FDA has cleared Protaryx Medical’s transseptal device, designed to improve access to the left side of the heart. The clearance could matter for structural heart and electrophysiology procedures where faster, more controlled access can influence both efficiency and safety.
Heartflow and Cleerly Fight Turns AI Imaging Competition Into a Patent War
Cardiovascular AI is moving beyond product competition and into legal conflict, with Heartflow suing rival Cleerly over patent claims. The case suggests that the next phase of AI imaging will be shaped as much by intellectual property as by algorithmic performance.
EU NextGen’s personalized cardiology effort shows where AI and data integration can genuinely improve precision care
The EU NextGen project’s push for personalized cardiology through AI and data integration reflects one of the most promising uses of healthcare AI: turning fragmented clinical and data streams into more individualized care. Cardiology is a particularly apt proving ground because outcomes often depend on combining imaging, biomarkers, history, and ongoing monitoring.
FDA Clears Anumana’s ECG-AI Tool to Flag Cardiac Amyloidosis From Routine ECGs
The FDA has cleared Anumana’s ECG-AI algorithm for detecting cardiac amyloidosis, a difficult-to-diagnose condition that often hides in plain sight on standard electrocardiograms. The move expands AI’s role from workflow support into earlier disease detection, where subtle patterns can change referral and treatment timelines.
Philips Wins FDA Clearance for AI Heart Valve Repair Solution
Philips has won FDA 510(k) clearance for an AI-enabled heart valve repair solution, adding to the company’s footprint in image-guided structural heart care. The clearance points to a growing market for software that helps clinicians plan and execute complex procedures with more precision.
Anumana’s ECG AI Clearance Brings Cardiac Amyloidosis Screening Closer to Routine Care
FDA clearance for Anumana’s 12-lead ECG-based AI algorithm for cardiac amyloidosis highlights the growing clinical ambition of signal-based diagnostics. The technology points to a future where common frontline tests become platforms for earlier identification of diseases that are often missed until late stages.
Etiometry Secures FDA Clearance for Cardiogenic Shock Classification AI, Extending Algorithms Into Acute-Care Operations
Etiometry says it has received the first FDA clearance for software that automates hospital-specific cardiogenic shock classification and tracking. The move underscores how AI is expanding beyond image interpretation into real-time operational support for high-acuity care.
Cardiology turns to interpretable machine learning as the demand for explainable risk tools grows
A Nature paper on stroke risk prediction in newly diagnosed atrial fibrillation underscores the field’s shift toward interpretable models. In cardiology, where decisions often hinge on trust and risk communication, explainability may matter almost as much as predictive power.
Anumana’s Pulmonary Hypertension Clearance Points to ECG AI’s Next Clinical Frontier
Anumana has secured FDA clearance for an ECG-based AI algorithm aimed at early detection of pulmonary hypertension. The development highlights the growing ambition of waveform AI: turning cheap, ubiquitous diagnostics into screening tools for conditions that are often missed until they are advanced.
ACC spotlights AI in cardiovascular care as the field shifts from imaging aid to earlier intervention
The American College of Cardiology outlines a future in which AI supports earlier detection and more data-driven action in cardiovascular medicine. The article stands out because cardiology is becoming one of the clearest examples of how multimodal healthcare AI may create value not just by reading images better, but by helping clinicians act sooner on risk.
Anumana’s FDA-cleared ECG AI for pulmonary hypertension shows where preventive cardiology is headed
Anumana secured FDA clearance for an ECG-based AI algorithm aimed at early detection of pulmonary hypertension, extending the push to find serious disease earlier in routine cardiovascular data. The clearance underscores how the ECG is becoming a scalable platform for AI-enabled risk discovery rather than just rhythm interpretation.
GE HealthCare’s ACC Showcase Reveals the New Imaging AI Competition: Platforms, Not Point Tools
GE HealthCare is spotlighting AI-enabled imaging technologies and advanced software at ACC.26, illustrating how major vendors are competing on integrated cardiovascular platforms. The strategic battle is moving beyond isolated algorithms toward end-to-end ecosystems spanning scanners, software, workflow, and analytics.
Noah Labs’ Breakthrough Designation Tests the Promise of Voice as a Cardiac Biomarker
Noah Labs has received FDA breakthrough device designation for an AI system that uses voice signals to monitor heart failure. The decision highlights growing regulatory openness to nontraditional digital biomarkers, while leaving the harder questions of clinical utility, workflow integration, and reimbursement still to be answered.
FDA clearance for Philips valve-repair guidance shows where imaging AI can win first
Philips says the FDA has cleared an AI solution that provides real-time guidance during complex minimally invasive heart valve repair. The approval highlights a commercially important direction for medical AI: narrow, procedural tools that augment specialist workflows at the point of care.
AI Plaque Analysis and FFR-CT Move Cardiac Imaging From Pictures to Decision Support
Cardiac imaging is shifting from anatomical visualization toward software-assisted risk and treatment guidance, with FFR-CT and AI plaque analysis taking a more central role. The change matters because it turns imaging from a diagnostic endpoint into a triage and management tool for coronary disease.
Cardiac MRI model with near-expert accuracy shows where imaging AI may scale next
A Medical Xpress report on an AI model reading cardiac MRI scans with near-expert accuracy suggests cardiovascular imaging is becoming a more important frontier for clinical AI. The real significance is not just performance, but the possibility of extending scarce specialist expertise in a complex, interpretation-heavy modality.
FDA Breakthrough nod for voice AI suggests heart failure screening is moving beyond imaging
Noah Labs’ breakthrough designation for a voice-based AI tool to detect heart failure signals growing FDA interest in nontraditional biomarkers. The development matters less as a single company milestone than as evidence that speech may become a clinically useful front door for cardiovascular screening and monitoring.
Viz.ai and Alnylam Push AI Into Rare Cardiac Disease Detection
A new partnership between Viz.ai and Alnylam Pharmaceuticals aims to improve detection of cardiac amyloidosis, a frequently underdiagnosed condition. The collaboration shows how AI is being used not only to speed common workflows, but to surface missed patients in high-value specialty disease areas.
Medtronic Broadens OmniaSecure Defibrillation Lead Labeling as EP Market Stays Competitive
Medtronic has won another FDA approval for its OmniaSecure defibrillation lead, expanding the product’s potential use in cardiac rhythm management. The move strengthens its position in electrophysiology and implantable cardiac devices, where incremental regulatory wins can materially shape share and physician preference.
Heart failure AI tool points to a higher-value use case: identifying the sickest patients sooner
Medical Xpress reports on an AI tool that shows promise in diagnosing advanced heart failure, a setting where earlier recognition could materially change care trajectories. The significance lies less in novelty alone and more in targeting a condition where delayed identification often drives avoidable deterioration and high-cost utilization.
Radiology Research Shows AI Reconstruction Can Sharpen Coronary CT Assessment
A February 2026 Radiology study highlighted by RSNA and indexed in PubMed found that super-resolution deep learning reconstruction improved coronary CT angiography assessment against invasive coronary angiography, with changes in CAD-RADS classification for a meaningful share of patients. The finding is notable because it points to AI’s growing role not just in detecting lesions, but in improving the underlying image reconstruction that shapes downstream diagnosis.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.